8-K

U.S. Securities and Exchange Commission
Washington, D.C. 20549

Form 8-K
Current Report

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

AUGUST 9, 2005

Date of Report (Date of earliest event Reported)

MESA LABORATORIES, INC.

(Exact Name of Small Business Issuer as Specified in its Charter)

Commission File Number: 0-11740

COLORADO	84-0872291
(State or other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
12100 WEST SIXTH AVENUE, LAKEWOOD, COLORADO	80228
(Address of Principal Executive Offices)	(Zip Code)

Issuer’s telephone number, including area code: (303) 987-8000

Not Applicable.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02 Results of Operations and Financial Condition.

        Pursuant to the interim guidance provided in Release No. 33-8216, the disclosure being furnished in this Form 8-K is being furnished under Item 12, “Results of Operations and Financial Condition,” of form 8-K.

        On August 9, 2005, Mesa Laboratories, Inc. issued a press release describing its results of operations for its first quarter ended June 30, 2005. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

          c)          Exhibits:

          99.1 Press Release issued August 9, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MESA LABORATORIES, INC.
	(Issuer)
DATED: August 9, 2005	BY:	/s/ LUKE R. SCHMIEDER
		Luke R. Schmieder
		President, Chief Executive Officer,
		Treasurer and Director

INDEX TO EXHIBITS

Exhibit No.	Description	Method of Filing
99.1	Press release dated August 9, 2005	Filed herewith

EX-99.1

Exhibit 99.1

Mesa Labs Reports First Quarter Sales and Earnings and Declares Quarterly Dividend

          LAKEWOOD, Colo., Aug. 9 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: MLAB) today reported sales and earnings for the fiscal first quarter ended June 30, 2005.

          For the first quarter of fiscal 2006, net sales decreased four percent to $2,440,000 from $2,539,000 in the same quarter last year.  Net income for the quarter decreased 14 percent to $540,000 or $.17 per diluted share compared to $625,000 or $.20 per diluted share one year ago.

          The Company experienced a sales decrease of four percent during the first quarter of the new fiscal year.  Medical products increased three percent, while the remainder of the company’s product lines decreased by 10 percent. Although shipments were down slightly during the quarter, order volume has shown increasing strength on a month to month basis through the first four months of the fiscal year.

          During the first quarter of fiscal 2006 the company began the process of converting the domestic distribution of its Datatrace products from independent manufacturer’s representatives to our own direct sales force. This change is expected to give us increased sales effort and better control of the selling effort.  To execute this strategy, two new direct sales representatives were added to the staff and a sales management position was converted to a field sales representative position.  These new hires, along with initial training, were completed during June.  For this reason, sales and marketing costs for the first quarter of fiscal 2006 increased significantly. As the year progresses, we expect to see a decrease in outside commissions which will partially off-set the compensation and travel costs of our new sales personnel.  We would also expect to benefit from higher sales later in the year due to the increased sales effort provided by our new sales staff.

          During the first quarter of the fiscal year, the Company repurchased 6,373 shares of our common stock under a previously announced buyback plan, and the Company’s cash position increased by $691,000 to $7,573,000.

          In other news, Mesa Laboratories, Inc. today announced that its Board of Directors has declared a regular quarterly cash dividend of six cents per share of common stock, payable on September 15, 2005 to shareholders of record at the close of business on September 1, 2005.

          Mesa Laboratories develops, acquires, manufactures and markets electronic instruments for industrial, pharmaceutical and medical applications.

          This news release contains forward-looking statements which involve risks and uncertainties.  The Company’s actual results could differ materially from those in any such forward-looking statements.  Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company’s Annual Report on Form-10KSB for the year ended March 31, 2005 as filed with the Securities and Exchange Commission, and from time to time in the Company’s other reports on file with the Commission.

FINANCIAL SUMMARY

STATEMENT OF EARNINGS (Unaudited)

	Quarter Ended June 30
	2005			2004
Net Sales	$	2,440,000		$	2,539,000
Cost of Goods		902,000			936,000
Gross Profit		1,538,000			1,603,000
Operating Expense		749,000			657,000
Operating Income		789,000			946,000
Other (Income) & Expense		(39,000	)		(15,000	)
Earnings Before Taxes		828,000			961,000
Income Taxes		288,000			336,000
Net Income	$	540,000		$	625,000
Earnings Per Share (Basic)	$	.18		$	.20
Earnings Per Share (Diluted)	$	.17		$	.20
Average Shares (Basic)		3,038,000			3,071,000
Average Shares (Diluted)		3,131,000			3,171,000

BALANCE SHEETS (Unaudited)

	June 30 2005		March 31 2005
Cash and Short-term Investments	$	7,573,000	$	6,882,000
Other Current Assets		3,775,000		4,241,000
Total Current Assets		11,348,000		11,123,000
Property and Equipment		1,279,000		1,265,000
Other Assets		4,208,000		4,208,000
Total Assets	$	16,835,000	$	16,596,000
Liabilities	$	1,176,000	$	1,217,000
Stockholders’ Equity		15,659,000		15,379,000
Total Liabilities and Equity	$	16,835,000	$	16,596,000

SOURCE  Mesa Laboratories, Inc.
          -0-                                                  08/09/2005
          /CONTACT:  Luke R. Schmieder, President-CEO, or Steven W. Peterson, VP Finance-CFO, both of Mesa Laboratories, Inc., +1-303-987-8000/